Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  American Review of Respiratory Disease

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/AJRCCM/145.1.212PMID 1309967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).

  1990cited by this paper
• Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254

  1989cited by this paper
• Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages.

  1988cited by this paper
• Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.

  1988cited by this paper
• [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].

  1988cited by this paper
• Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex.

  1988cited by this paper
• In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.

  1987cited by this paper
• Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes

  1987cited by this paper
• Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods.

  1987cited by this paper
• In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.

  1987cited by this paper
• Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250.

  1985cited by this paper
• Uptake of antibiotics by human alveolar macrophages.

  1984cited by this paper
• LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies.

  1983cited by this paper

• Updates in the Treatment of Active and Latent Tuberculosis

  2018cites this paper
• Host-Factor Enhancement of Therapy for Tuberculosis By Michael David Schump A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Infectious Diseases and Immunity

  2015cites this paper
• Host-Factor Enhancement of Therapy for Tuberculosis

  2015cites this paper
• A review of rifapentine for treating active and latent tuberculosis

  2015cites this paper
• In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.

  2013cites this paper
• Mechanisms of upper airway hypotonia

  2011cites this paper
• Rifamycins e Obstacles and opportunities

  2010cites this paper
• Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

  2010cites this paper
• Rifamycins--obstacles and opportunities.

  2010cites this paper
• Mycobacterium microti – pulmonary tuberculosis in an immunocompetent patient

  2009cites this paper
• Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.

  2006cites this paper
• The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.

  2005cites this paper
• Flow-regulatory function of upper airway in health and disease: A unified pathogenetic view of sleep-disordered breathing

  2004cites this paper
• Effect of Sex and AIDS Status on the Plasma and Intrapulmonary Pharmacokinetics of Rifampicin

  2004cites this paper
• Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.

  2004cites this paper
• Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin

  2003cites this paper
• Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.

  2003cites this paper
• Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis

  2003influential citation
• Mechanisms of Airway Hypotonia

  2002cites this paper
• Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials

  2001cites this paper
• Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice

  2000cites this paper
• Prospects for development of new antimycobacterial drugs

  2000cites this paper
• Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model

  2000cites this paper
• Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.

  2000cites this paper
• Nanoparticles as Antituberculosis Drugs Carriers: Effect on Activity Against Mycobacterium tuberculosis in Human Monocyte-Derived Macrophages

  2000cites this paper
• Single-Dose Intrapulmonary Pharmacokinetics of Rifapentine in Normal Subjects

  2000cites this paper
• Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid Media

  1999cites this paper
• Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice

  1999cites this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

  1999cites this paper
• Rifapentine: Its Role in the Treatment of Tuberculosis

  1999cites this paper
• Pharmacokinetic Factors in the Modern Drug Treatment of Tuberculosis

  1999cites this paper
• Development of Rifapentine Susceptibility Tests forMycobacterium tuberculosis

  1999cites this paper
• Pulmonary tuberculosis.

  1999cites this paper
• The Treatment of Tuberculosis

  1998cites this paper
• Animal Models for Tuberculosis Research

  1998cites this paper
• Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model

  1998cites this paper
• Mycobacterial infection models.

  1998cites this paper
• Comparison of biological and chemical assays for the quantitation of rifapentine in human plasma.

  1997cites this paper
• Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis.

  1997cites this paper
• Synthesis of Nucleosidyl Rifamycins as Inhibitors of Human Immunodeficiency Virus Type 1

  1997cites this paper
• Treatment of Tuberculosis: Current Status and Future Promise

  1997cites this paper
• Antimicrobial activity of rifabutin.

  1996cites this paper
• Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages

  1996cites this paper
• Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

  1996cites this paper
• Reporter gene technology to assess activity of antimycobacterial agents in macrophages

  1996cites this paper
• Antimicrobial activity of rifabutin. Discussion

  1996cites this paper
• Methods for determining concentrations of antimicrobial agents in human monocytes.

  1995cites this paper
• Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages

  1995cites this paper
• Treatment and developmental therapeutics of Mycobacterium tuberculosis infections

  1994cites this paper
• Treatment and developmental therapeutics of Mycobacterium tuberculosis infections.

  1994cites this paper
• Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium

  1994cites this paper
• Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.

  1993cites this paper
• Upper airway dilating muscle hyperactivity during non-rapid eye movement sleep in English bulldogs.

  1993cites this paper
• A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.

  1992cites this paper
• The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.

  1992cites this paper